Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel

Daytraders Terug naar discussie overzicht

Centessa Pharmaceuticals (NASDAQ:CNTA)

1 Post
| Omlaag ↓
  1. [verwijderd] 8 juni 2022 15:59
    Centessa Pharmaceuticals (NASDAQ:CNTA) Lifted to “Buy” at Zacks Investment Research
    Posted by admin on Jun 6th, 202

    Pharmaceuticals logoCentessa Pharmaceuticals (NASDAQ:CNTA – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday, Zacks.com reports. The brokerage currently has a $3.50 price objective on the stock. Zacks Investment Research‘s price objective would suggest a potential upside of 10.06% from the stock’s current price.

    According to Zacks, “Centessa Pharmaceuticals plc is a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients. Centessa Pharmaceuticals plc is based in Cambridge, United Kingdom. “

    Get Centessa Pharmaceuticals alerts:
    Enter Your Email Address
    A number of other equities research analysts also recently commented on CNTA. The Goldman Sachs Group cut their price objective on Centessa Pharmaceuticals from $12.00 to $8.00 and set a “neutral” rating for the company in a research report on Tuesday, May 24th. Morgan Stanley decreased their price objective on shares of Centessa Pharmaceuticals from $19.00 to $15.00 and set an “overweight” rating for the company in a report on Tuesday, May 24th. Finally, Jefferies Financial Group cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $4.00 price target for the company. in a report on Friday.

    Centessa Pharmaceuticals stock traded down $0.05 during midday trading on Monday, hitting $3.18. The stock had a trading volume of 5,782,580 shares, compared to its average volume of 249,128. The stock has a market cap of $299.05 million and a P/E ratio of -1.34. The business has a fifty day moving average price of $7.37 and a 200 day moving average price of $9.13. Centessa Pharmaceuticals has a 12 month low of $2.88 and a 12 month high of $26.90. The company has a current ratio of 21.37, a quick ratio of 21.37 and a debt-to-equity ratio of 0.16.
    Centessa Pharmaceuticals (NASDAQ:CNTA – Get Rating) last issued its quarterly earnings data on Monday, May 16th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.09. On average, equities analysts anticipate that Centessa Pharmaceuticals will post -2.48 EPS for the current fiscal year.

    In related news, EVP Antoine Yver sold 20,222 shares of the company’s stock in a transaction on Tuesday, May 17th. The shares were sold at an average price of $5.42, for a total value of $109,603.24. Following the completion of the transaction, the executive vice president now directly owns 813,675 shares of the company’s stock, valued at approximately $4,410,118.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 9.09% of the stock is owned by insiders.

    A number of institutional investors have recently added to or reduced their stakes in CNTA. Point72 Asset Management L.P. boosted its position in shares of Centessa Pharmaceuticals by 263.3% during the 4th quarter. Point72 Asset Management L.P. now owns 1,097,908 shares of the company’s stock worth $12,362,000 after acquiring an additional 795,708 shares in the last quarter. Virtus ETF Advisers LLC acquired a new stake in Centessa Pharmaceuticals in the fourth quarter worth $167,000. General Atlantic L.P. grew its holdings in Centessa Pharmaceuticals by 545.5% in the third quarter. General Atlantic L.P. now owns 9,681,818 shares of the company’s stock worth $161,686,000 after purchasing an additional 8,181,818 shares during the period. Boxer Capital LLC grew its holdings in shares of Centessa Pharmaceuticals by 47.6% during the third quarter. Boxer Capital LLC now owns 1,334,227 shares of the company’s stock valued at $22,282,000 after buying an additional 430,000 shares during the last quarter. Finally, RA Capital Management L.P. grew its holdings in shares of Centessa Pharmaceuticals by 179.4% during the third quarter. RA Capital Management L.P. now owns 3,577,094 shares of the company’s stock valued at $59,737,000 after buying an additional 2,296,794 shares during the last quarter. 95.72% of the stock is currently owned by hedge funds and other institutional investors.

    About Centessa Pharmaceuticals (Get Rating)

    Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B.
1 Post
|Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 465 6.840
AB InBev 2 5.286
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.580 46.467
ABO-Group 1 19
Acacia Pharma 9 24.692
Accell Group 151 4.129
Accentis 2 253
Accsys Technologies 22 8.960
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 160
ADMA Biologics 1 31
Adomos 1 126
AdUX 2 457
Adyen 13 16.498
Aedifica 2 832
Aegon 3.257 320.099
AFC Ajax 537 7.018
Affimed NV 2 5.762
ageas 5.843 109.779
Agfa-Gevaert 13 1.862
Ahold 3.536 73.983
Air France - KLM 1.024 34.350
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 466 12.774
Alfen 12 16.553
Allfunds Group 3 1.217
Almunda Professionals (vh Novisource) 651 4.247
Alpha Pro Tech 1 17
Alphabet Inc. 1 338
Altice 106 51.196
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.485 114.767
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.821 240.371
AMG 965 125.878
AMS 3 73
Amsterdam Commodities 303 6.523
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 382
Antonov 22.632 153.605
Aperam 91 14.164
Apollo Alternative Assets 1 17
Apple 5 319
Arcadis 251 8.623
Arcelor Mittal 2.024 318.674
Archos 1 1
Arcona Property Fund 1 267
arGEN-X 15 9.113
Aroundtown SA 1 176
Arrowhead Research 5 9.283
Ascencio 1 20
ASIT biotech 2 697
ASMI 4.107 37.706
ASML 1.762 77.072
ASR Nederland 18 4.124
ATAI Life Sciences 1 7
Atenor Group 1 333
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 29 10.679
Axsome Therapeutics 1 177
Azelis Group 1 49
Azerion 7 2.681

Beleggingsideeën van onze partners

Macro & Bedrijfsagenda

  1. 06 mei

    1. China inkoopmanagersindex diensten april
    2. PostNL Q1-cijfers
    3. Siemens Healthineers Q1-cijfers
    4. TKH Q1-cijfers
    5. Dui inkoopmanagersindex diensten april (def)
    6. EU inkoopmanagersindex diensten april (def) 52,9
    7. VK inkoopmanagersindex diensten april (def)
    8. EU producentenprijzen maart
    9. Tyson Foods Q1-cijfers
  2. 07 mei

    1. Japan inkoopmanagersindex diensten april
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht